Naru Kondo1, Kenichiro Uemura1, Naoya Nakagawa1, Kenjiro Okada1, Shintaro Kuroda2, Takeshi Sudo3, Naoto Hadano3, Hiroyoshi Matstukawa4, Daisuke Satoh4, Masaru Sasaki5, Tomoyuki Abe6, Saburo Fukuda7, Akihiko Oshita8, Akira Nakashima9, Yasushi Hashimoto10, Hideki Ohdan2, Yoshiaki Murakami11. 1. Department of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan. 2. Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan. 3. Department of Surgery, Kure Medical Center and Chugoku Cancer Center, Kure, Japan. 4. Department of Gastroenterological Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan. 5. Department of Surgery, Hiroshima General Hospital, Hatsukaichi, Japan. 6. Department of Surgery, Onomichi General Hospital, Onomichi, Japan. 7. Department of Surgery, Chugoku Rosai Hospital, Kure, Japan. 8. Department of Gastroenterological Surgery, Hiroshima Prefectural Hospital, Hiroshima, Japan. 9. Department of Surgery, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan. 10. Department of Surgery, Hiroshima Memorial Hospital, Hiroshima, Japan. 11. Department of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan. mura777@hiroshima-u.ac.jp.
Abstract
BACKGROUND: Although distal pancreatectomy (DP) using a reinforced stapler is expected to reduce PF, no multicenter RCT has been performed. To investigate whether reinforced staplers reduce the incidence of clinically relevant pancreatic fistula (PF) after DP compared with staplers without reinforcement. METHODS:Between July 2016 and December 2017, patients scheduled for DP were enrolled in a multicenter, randomized, controlled trial (RCT) at nine hospitals in Hiroshima Japan. Patients were randomized either to reinforced stapler or bare stapler. The primary endpoint was incidence of clinically relevant PF. This RCT was registered with UMIN Clinical Trial Registry (UMIN000022341). RESULTS: A total of 122 patients were assigned to reinforced stapler (n = 61) or bare stapler (n = 61), and 119 patients (61reinforced stapler and 59 bare stapler) were analyzed. There was no significant difference in the incidence of clinically relevant PF between the reinforced stapler and bare stapler groups (16.3% vs. 27.1%, p = 0.15). Furthermore, the rates of major complication (16.3% vs. 18.6%, p = 0.74), postpancreatectomy hemorrhage (0% vs. 3.4%, p = 0.08), and median postoperative in-hospital days (19 days vs. 20 days, p = 0.78) did not differ between the two groups. Within a subset of 82 patients in whom the thickness of pancreatic transection line was less than 14 mm, a significant difference was found in the incidence of clinically relevant PF (4.5% vs. 21.0% in the reinforced stapler vs. bare stapler groups, respectively, p = 0.01). CONCLUSIONS: Reinforced stapler for pancreatic transection during DP does not reduce the incidence of clinically relevant PF compared to stapler without reinforcement.
RCT Entities:
BACKGROUND: Although distal pancreatectomy (DP) using a reinforced stapler is expected to reduce PF, no multicenter RCT has been performed. To investigate whether reinforced staplers reduce the incidence of clinically relevant pancreatic fistula (PF) after DP compared with staplers without reinforcement. METHODS: Between July 2016 and December 2017, patients scheduled for DP were enrolled in a multicenter, randomized, controlled trial (RCT) at nine hospitals in Hiroshima Japan. Patients were randomized either to reinforced stapler or bare stapler. The primary endpoint was incidence of clinically relevant PF. This RCT was registered with UMIN Clinical Trial Registry (UMIN000022341). RESULTS: A total of 122 patients were assigned to reinforced stapler (n = 61) or bare stapler (n = 61), and 119 patients (61 reinforced stapler and 59 bare stapler) were analyzed. There was no significant difference in the incidence of clinically relevant PF between the reinforced stapler and bare stapler groups (16.3% vs. 27.1%, p = 0.15). Furthermore, the rates of major complication (16.3% vs. 18.6%, p = 0.74), postpancreatectomy hemorrhage (0% vs. 3.4%, p = 0.08), and median postoperative in-hospital days (19 days vs. 20 days, p = 0.78) did not differ between the two groups. Within a subset of 82 patients in whom the thickness of pancreatic transection line was less than 14 mm, a significant difference was found in the incidence of clinically relevant PF (4.5% vs. 21.0% in the reinforced stapler vs. bare stapler groups, respectively, p = 0.01). CONCLUSIONS: Reinforced stapler for pancreatic transection during DP does not reduce the incidence of clinically relevant PF compared to stapler without reinforcement.